Patients get printed drug safety info with every prescription—manufacturers bear the cost
H.R. 5133 — Patients’ Right to Know Their Medication Act of 2025 · Filed by Cliff Bentz (R-OR) · 11 cosponsors · Introduced Sep 4, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires pharmaceutical manufacturers to include a standardized, single-page printed patient medication information sheet with every prescription drug dispensed in non-hospital settings. The FDA must issue regulations within one year specifying the format, content, language, graphics, and distribution requirements. The sheet must include drug name, indications, directions, contraindications, warnings, adverse reactions, interactions, storage/disposal instructions, manufacturer contact info, and a link to report adverse events. Failure to include this printed information would constitute misbranding.
Why we flagged it
The bill's operative mechanism is a mandatory disclosure requirement—manufacturers must provide standardized printed patient information with every prescription. This is a consumer-protection and public-health measure, not a tax provision, subsidy, or deregulation. The character is straightforward patient safety.
What the text implies
- Manufacturers may face significant printing and packaging costs, which could be passed to insurers, pharmacy benefit managers, or patients through higher drug prices or copays, offsetting some of the bill's cost-savings claims.
- The bill requires FDA to develop regulations within one year; if the agency lacks resources or prioritizes other rulemakings, implementation delays could push the effective date well beyond the statutory deadline.
The full analysis lists 5 implications of this text.
Who stands to gain
printing and packaging service providers; pharmaceutical manufacturers (regulatory clarity and safe harbor from certain liability claims); pharmacy benefit managers and insurers (potential long-term savings from reduced adverse events)